drugset / Trial / NCT06592924
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Phase 3
Recruiting
830 enrolled
Canadian Cancer Trials Group
Alliance for Clinical Trials in Oncology · collabECOG-ACRIN Cancer Research Group · collabNRG Oncology · collabSWOG Cancer Research Network · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach for patients who are not in a study is hormone treatment with Androgen Deprivation Therapy (ADT) and Androgen-Receptor Pathway Inhibitor (ARPI).
Timeline
- Start
- 2025-05-28
- Primary completion
- 2031-03-14
- Completion
- 2031-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Apalutamide | Small molecule | — | — |
| Background | Darolutamide | Other / unclassified | — | — |
| Background | Enzalutamide | Other / unclassified | — | — |